上市公司资料
 
荣昌生物制药(烟台)股份有限公司 股票代号:  09995
REMEGEN CO., LTD. 集团网址: http://www.remegen.com
损益表
  2024/12
RMB($)
变动 2023/12
RMB($)
2022/12
RMB($)
营业额1,710,152,00058.917%1,076,130,000767,775,000
经营溢利/(亏损)(1,468,258,000)--(1,511,184,000)(998,830,000)
特殊项目--------
摊占联营公司及共同控制公司溢利/(亏损)(104,000)--(45,000)0
税前溢利/(亏损)(1,468,362,000)--(1,511,229,000)(998,830,000)
税项0--00
少数股东权益0--00
股东应占溢利/(亏损)(1,468,362,000)--(1,511,229,000)(998,830,000)
 
净利息收入/(支出)(62,140,000)--5,052,00054,786,000
折旧与摊销302,729,00025.721%240,794,000186,803,000
董事酬金35,236,000-36.912%55,852,00057,425,000
 
每股盈利/(亏损)(仙)(273.000)--(280.000)(188.000)
每股派息(仙)0.000--0.0000.000
 
派息比率(%)--------
每股帐面资产净值($)3.649-42.223%6.3159.151
主要财务比率
  2024/12
RMB($)
变动 2023/12
RMB($)
2022/12
RMB($)
经营边际利润率(%)(85.855)%--(140.428)%(130.094)%
利息盈利率(x)--------
资产回报率(%)(26.633)%--(26.170)%(19.623)%
股东资金回报率(%)(54.148)%--(35.907)%(23.706)%

 

Copyright © 2026 ET Net Limited. All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.